Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

We found no significant association for liver parameters and undiagnosed celiac seropositivity, nor for fasting blood sugar, serum 25-hydroxy Vitamin D or serum Vitamin B12.Comparison of levels of biomarkers between cases and controlsN measurements (n cases/ n controls)Cases: Celiac disease antibody positive participantsaControlsOR (95% CI)bNumber of participants169676Median (5%/95%)Median (5%/95%)Cholesterol (mmol/L)*790 (cases:158/controls:632)5.5 (3.7/8.0)5.7 (4.1/7.8) 1st quartile1.56 (0.92 to 2.62) 2nd quartile1.02 (0.60 to 1.74) 3rd quartile0.84 (0.50 to 1.43) 4th quartileRef% (n/N)% (n/ total N )Cholesterol under 5 mmol/L37.3 (59/158)28.3 (179/632)1.60 (1.08 to 2.37)Median (5%/95%)Median (5%/95%)Hemoglobin (mmol/L)*235 (cases:48/controls:187)8.4 (7.2/9.8)8.6 (7.6/9.9) 1st quartile1.44 (0.47 to 4.40) 2nd quartile0.63 (0.21 to 1.83) 3rd quartile0.63 (0.21 to 1.88) 4th quartileRef% (n/ total N )% (n/N)Low hemoglobinc12.5 (6/48)4.3 (8/187)3.82 (1.14 to 12.79)Median (5%/95%)Median (5%/95%)Fasting blood glucose (mmol/L)*549 (cases:110/controls:439)4.8 (4.0/6.0)4.8 (3.9/6.3) 1st quartile0.84 (0.46 to 1.54) 2nd quartile1.00 (0.56 to 1.79) 3rd quartile0.68 (0.38 to 1.23) 4th quartileRefFasting blood glucose over 7 mmol/L1.8 (2/110)2.5 (11/439)0.69 (0.14 to 3.48)Median (5%/95%)Median (5%/95%)HbA1c (%)*474 (cases:95/controls:379)5.8 (4.9/6.5)5.8 (5.0/6.5) 1st quartile1.26 (0.61 to 2.57) 2nd quartile1.01 (0.53 to 1.92) 3rd quartile1.14 (0.62 to 2.08) 4th quartileRefMedian (5%/95%)Median (5%/95%)Ferritin (µg/L)*455 (cases:92/controls:363)74.5 (6.0/311.0)78.0 (8.0/298.0) 1st quartile1.41 (0.65 to 3.05) 2nd quartile0.72 (0.36 to 1.43) 3rd quartile0.69 (0.35 to 1.34) 4th quartileRefALAT (Alanine transaminase)* (U/L)465 (cases:94/controls:371)10.8 (6.6/33.0)10.2(6.6/32.0) 1st quartile0.67 (0.17 to 2.73) 2nd quartile0.63 (0.15 to 2.56) 3rd quartile1.43 (0.41 to 4.07) 4th quartileRefASAT (Aspartate aminotransferase) (U/L)*35 (cases:7/controls:28)20.0 (14.0/28.0)17.5 (13.0/38.0) 1st quartile0.63 (0.08 to 5.26) 2nd quartile0.37 (0.04 to 4.01) 3rd quartile0.34 (0.03 to 4.41) 4th quartileRefAlkaline phosphatase (ALP)* (U/L)385 (cases:77/controls:308)48.0 (28.2/90.0)44.4 (28.2/72.0) 1st quartile0.69 (0.34 to 1.40) 2nd quartile0.63 (0.32 to 1.25) 3rd quartile0.60 (0.30 to 1.20) 4th quartileRef% (n/ total N )% (n/ total N )Elevated liver parameters (ASAT/ALAT/ALP)d1.0 (1/102)2.2 (9/407)0.42 (0.05 to 3.48)Median (5%/95%)Median (5%/95%)Vitamin D (nmol/L)*474 (cases:95/controls:379)50.0 (10.0/107.0)54.0 (13.0/102.0) 1st quartile1.21 (0.63 to 2.30) 2nd quartile1.41 (0.76 to 2.65) 3rd quartile1.05 (0.55 to 2.01) 4th quartileRefVitamin B12 (pmol/L)*385 (cases:77/controls:308)286.3 (159.4/513.6)295.9 (170.5/492.2) 1st quartile1.22 (0.63 to 2.38) 2nd quartile0.81 (0.39 to 1.69) 3rd quartile0.64 (0.30 to 1.36) 4th quartileRef*The quartiles were calculated per each of the eight studiesStatistically significant values are shown in boldaThe participants were screened for celiac disease antibodies by EliA™ Celikey® tissue transglutaminase (TTG) anti-IgA and anti-IgG assays and deamidated gliadin peptide (DGP) anti-IgG assays.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

As described earlier [], we used data from eight population-based studies carried out during 1976 to 2012 at the Center for Clinical Research and Prevention; The 5-year follow-up of The Health 2006 study [, ], The Inter99 study [, ], The 1936-cohort study [], The Monica-I study [], The Monica-II study [], The Monica-III study [, ], The 1914-cohort study [, ], and The Allergy 90 study [, ].

Source: Methods.

Participants were invited to a health examination including self-administered questionnaires and blood sampling.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Symptoms and biomarkers associated with undiagnosed celiac seropositivity

Cohort study · BMC Gastroenterology · 2021

Original publication title

Symptoms and biomarkers associated with undiagnosed celiac seropositivity

Line Lund Kårhus; Janne Petersen; Katja Biering Leth-Møller; Line Tang Møllehave; Anja Lykke Madsen; Betina Heinsbæk Thuesen; Peter Schwarz; Jüri J. Rumessen; Allan Linneberg

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In this general population study, undiagnosed cases of celiac seropositivity did not have more symptoms than controls, confirming the diagnostic difficulties of celiac disease and the low prognostic value of symptoms for a diagnosis of celiac disease. Furthermore, decreased levels of cholesterol and/or hemoglobin in the blood were associated with undiagnosed celiac seropositivity.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Studies have indicated that underdiagnosis and diagnostic delay are common in celiac disease. Therefore, it is important to increase our knowledge of what symptoms and biomarkers could identify undiagnosed cases of celiac disease.

Source: Background

Abstract: What methods does the paper describe?

We screened for celiac disease antibodies in stored blood samples from 16,776 participants in eight population-based studies examined during 1976 to 2012. Undiagnosed celiac seropositivity was defined as celiac disease antibody positivity (IgG-deamidated gliadin peptide above 10.0 U/mL and/or IgA-tissue transglutaminase (TTG) or IgG-TTG above 7.0 U/mL) without a known diagnosis of celiac disease in the National Patient Register. In all studies general health symptoms were recorded by participant-completed questionnaire, including self-perceived health, tiredness, headache and gastrointestinal symptoms. Furthermore, blood samples were drawn for analyses of biomarkers e.g. hemoglobin, blood glucose, cholesterol, liver parameters and vitamins.

The participants with undiagnosed celiac seropositivity were matched by sex, age and study with four controls among the celiac disease antibody negative participants.

Source: Methods

Abstract: Results

We excluded, five participants with known celiac disease, resulting in a population of 16,771 participants. In this population 1% (169/16,771) had undiagnosed celiac seropositivity. There were no statistically significant differences in symptoms between cases and controls. Undiagnosed celiac seropositivity was associated with low blood cholesterol (< 5 mmol/L) and low hemoglobin (< 7.3 mmol/L for women and < 8.3 mmol/L for men).

Source: Results

Abstract: Conclusion

In this general population study, undiagnosed cases of celiac seropositivity did not have more symptoms than controls, confirming the diagnostic difficulties of celiac disease and the low prognostic value of symptoms for a diagnosis of celiac disease. Furthermore, decreased levels of cholesterol and/or hemoglobin in the blood were associated with undiagnosed celiac seropositivity.

Source: Conclusion
Authors’ abstract

Background

Studies have indicated that underdiagnosis and diagnostic delay are common in celiac disease. Therefore, it is important to increase our knowledge of what symptoms and biomarkers could identify undiagnosed cases of celiac disease.

Methods

We screened for celiac disease antibodies in stored blood samples from 16,776 participants in eight population-based studies examined during 1976 to 2012. Undiagnosed celiac seropositivity was defined as celiac disease antibody positivity (IgG-deamidated gliadin peptide above 10.0 U/mL and/or IgA-tissue transglutaminase (TTG) or IgG-TTG above 7.0 U/mL) without a known diagnosis of celiac disease in the National Patient Register. In all studies general health symptoms were recorded by participant-completed questionnaire, including self-perceived health, tiredness, headache and gastrointestinal symptoms. Furthermore, blood samples were drawn for analyses of biomarkers e.g. hemoglobin, blood glucose, cholesterol, liver parameters and vitamins.

The participants with undiagnosed celiac seropositivity were matched by sex, age and study with four controls among the celiac disease antibody negative participants.

Results

We excluded, five participants with known celiac disease, resulting in a population of 16,771 participants. In this population 1% (169/16,771) had undiagnosed celiac seropositivity. There were no statistically significant differences in symptoms between cases and controls. Undiagnosed celiac seropositivity was associated with low blood cholesterol (< 5 mmol/L) and low hemoglobin (< 7.3 mmol/L for women and < 8.3 mmol/L for men).

Conclusion

In this general population study, undiagnosed cases of celiac seropositivity did not have more symptoms than controls, confirming the diagnostic difficulties of celiac disease and the low prognostic value of symptoms for a diagnosis of celiac disease. Furthermore, decreased levels of cholesterol and/or hemoglobin in the blood were associated with undiagnosed celiac seropositivity.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12876-021-01667-y.

Publication and source details

Original title: Symptoms and biomarkers associated with undiagnosed celiac seropositivity

Line Lund Kårhus; Janne Petersen; Katja Biering Leth-Møller; Line Tang Møllehave; Anja Lykke Madsen; Betina Heinsbæk Thuesen; Peter Schwarz; Jüri J. Rumessen; Allan Linneberg

BMC Gastroenterology · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T13:21:57.739317+00:00

DOI: 10.1186/s12876-021-01667-y · PMC7913457